IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights

NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines based on its T-win^® platform, today reported financial results for the third quarter ended September 30, 2024.

Read more at globenewswire.com